Prime Sciences Warning Letter - Unapproved New Drugs Sold Online

The FDA issued a warning letter to Prime Sciences (Scottsdale, AZ) for selling unapproved new drugs online through their website. The products at issue include Cagrilintide, GLP1-R (Retatrutide), GLP1-S (Semaglutide), GLP1-T (Tirzepatide), Mazdutide, and BAC water. These products are being marketed for human use in weight loss and diabetes management despite labeling that claims 'research purposes only' and 'not for human consumption.' The FDA determined these are unapproved new drugs under Section 505(a) of the FD&C Act.

Warning Letter - PekCura Labs - Unapproved GLP-1 Drugs Sold Online

FDA issued a Warning Letter to PekCura Labs (Pensacola, FL) on March 31, 2026, for selling unapproved new drugs including GLP-1-S, GLP-2-T, GLP-3-R, and Bacteriostatic Water through their website. The products are unapproved drugs under Section 505(a) of the FD&C Act, despite labeling claims that they are for 'research use only' and 'not for human consumption.' The FDA determined these injectable products pose serious public health risks because they bypass natural body defenses when delivered directly into the bloodstream.

Medline Industries LP - Quality System Regulation Violations Warning Letter

FDA issued a Warning Letter to Medline Industries, LP (NAMIC Division) citing Quality System Regulation violations under 21 CFR Part 820. The inspection conducted December 1-12, 2025 identified CAPA procedure failures involving NAMIC Angiographic Control Syringes that generated 221 complaints and 177 MDRs, including documented cases of air embolism patient harm and biohazard exposure to clinicians.

FDA Warning Letter to Guangzhou Huli Technology Co. Ltd. for Unapproved GLP-1 Drug Sales

The FDA's Center for Drug Evaluation and Research issued a Warning Letter to Guangzhou Huli Technology Co., Ltd. (dba Fantasy Face) on March 31, 2026, for selling unapproved new drugs through its eBay store. The company's 'Googeer GLP-1 Weight Control Oral Solution' is marketed as a weight loss and metabolism support product but lacks FDA approval under Section 505 of the FD&C Act. The FDA has demanded the company respond within 15 working days with corrective actions or face potential seizure and injunction.

Unapproved New Drugs - GLP-1/GIP/Glucagon Peptide Compounds

FDA issued a Warning Letter to Mile High Compounds LLC for marketing unapproved new drugs, including GLP-1 SM, GLP-2 TRZ, and GLP-3 RT peptide compounds, via their website. The agency determined these products are drugs under section 201(g)(1) of the FD&C Act because labeling and marketing materials make therapeutic claims for weight loss, addiction recovery, and metabolic control despite labeling disclaimers. The FDA cites violations of sections 301(d) and 505(a) of the FD&C Act for introducing unapproved drugs into interstate commerce.

Pink Pony Peptides - Unapproved New Drugs Warning

FDA issued a Warning Letter to Lovega LLC dba Pink Pony Peptides for marketing and selling unapproved new drugs, including peptide products GLP-2 TZ, GLP-3 RT, and Bacteriostatic Water. The products were found to be marketed with therapeutic claims despite labeling stating 'not for human consumption.' FDA determined the products meet the definition of new drugs under the FD&C Act and require approved applications before sale.

The Sunset Rule-Aircraft Impact Assessment

The U.S. Nuclear Regulatory Commission has amended 10 CFR Part 50 to insert a conditional sunset date for aircraft impact assessment requirements. This final rule implements Executive Order 14270, "Zero-Based Regulatory Budgeting to Unleash American Energy," by establishing a mechanism for automatically repealing these requirements unless affirmatively renewed. The action affects nuclear power plant licensees and applicants who must comply with aircraft impact assessment regulations.

Garcia v. Dove - Appeal Dismissed for Untimely Filing

The Fourth Circuit dismissed Jerome Garcia's appeal for lack of jurisdiction because his notice of appeal was not timely filed. The district court had dismissed his 42 U.S.C. § 1983 complaint as frivolous on November 25, 2025, and Garcia did not file his notice of appeal until February 17, 2026—well past the 30-day deadline that expired on December 26, 2025.

Mark Vogel Acquisitions v. Prince George's County - Racial Discrimination

The Fourth Circuit affirmed the District of Maryland's dismissal of racial discrimination claims brought by Mark Vogel and his companies against Prince George's County, Maryland. The court upheld dismissal of claims under 42 U.S.C. §§ 1981, 1983, and 1985(3), finding the complaint contained only conclusory assertions of disparate treatment without sufficient factual matter to state a plausible claim for relief under Ashcroft v. Iqbal and Bell Atlantic Corp. v. Twombly standards.

Piscitelli v. GitLab, Inc. - Title VII Employment Discrimination

The Fourth Circuit affirmed the district court's dismissal of Brian Piscitelli's Title VII claims against GitLab, Inc. The court rejected Piscitelli's argument that the district court should have applied the Tenth Circuit's modified prima facie test for religious discrimination, finding it conflicts with Fourth Circuit precedent. The plaintiff alleged religious discrimination after being terminated for security clearance lapse while seeking COVID-19 vaccine religious accommodation.